Phil D Alexander

Phil Alexander serves as a primary contracting professional within the CDC Office of Acquisition Services, overseeing the procurement of critical public health infrastructure and scientific services that directly support the agency’s mission to detect, respond to, and prevent infectious disease threats. He manages a diverse portfolio of acquisitions centered on laboratory diagnostics, biomedical research tools, and data-driven epidemiological systems, ensuring timely access to mission-critical technologies and expert consulting services. His work enables the CDC’s rapid response capabilities and strengthens national laboratory capacity through strategic sourcing aligned with federal acquisition regulations and public health priorities. Alexander maintains established relationships with leading contractors including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, and Cepheid, partnering with organizations capable of delivering high-complexity diagnostic equipment, analytical instrumentation, and scientific technical services. These vendor relationships are characterized by long-term collaboration on mission-essential procurements requiring rigorous compliance with biosafety, data integrity, and regulatory standards. His contracting approach prioritizes technical proficiency, supply chain reliability, and performance-based outcomes over cost alone. His procurement patterns reflect a strong preference for full and open competition, with 98.8% of awards issued without set-aside designations. While small business participation is limited in volume, he remains compliant with FAR 19.5 requirements, occasionally awarding to total small business set-asides when market conditions support it, demonstrating adherence to socioeconomic goals without compromising mission readiness. Alexander’s primary NAICS focus areas include analytical laboratory instrument manufacturing (334516), scientific and technical consulting services (541690), and broader professional scientific services (541990). He routinely procures next-generation PCR systems, biosafety-grade equipment, bioinformatics platforms, and specialized epidemiological analysis services, underscoring deep expertise in life sciences procurement and public health technology acquisition.